TJM Labs Appoints John M. Connolly as Independent Board Member

Veteran technology executive and board director brings decades of experience scaling high-growth companies and developing executive teams

WILMINGTON, DE, UNITED STATES, August 27, 2026 /EINPresswire.com/ — TJM Labs, the leading pharmacy AI platform, today announced the appointment of John M. Connolly as an independent member of its Board of Directors. Connolly brings 30 years of experience building, leading, and advising high-growth technology companies as a CEO, founder, investor, and board director.

Connolly joins TJM Labs as the company enters its next stage of growth, following significant expansion across the pharmacy industry. He will work closely with Founder and CEO Jonathan Adly and the company’s leadership team on the organizational and strategic decisions required to scale the business, with a particular focus on organizational design, executive development, go-to-market strategy, and translating rapid growth into durable long-term advantage.

“John has spent his career helping ambitious companies navigate the decisions that come with rapid growth,” said Jonathan Adly, Founder and CEO of TJM Labs. “He brings the perspective of a five-time CEO, a two-time founder and a board director who has helped companies like Fleetio, Limble, A Cloud Guru and others navigate their highest-growth years. As TJM enters this next stage, he’ll be an important partner to me and our leadership team as we scale the organization, develop our executives, and build a company positioned to lead this market for the long term.”

Over the course of his career, Connolly has served as chairman, non-executive chairman, or director on more than 50 boards. He is the Founder and Managing Director of Eaglehead Capital and serves as a Lead Advisor to Goldman Sachs Growth. His work focuses on partnering with CEOs, management teams, and boards to address the strategic and operational challenges that emerge as companies scale.

Connolly has advised leaders across areas including executive management, organizational development, go-to-market strategy and market segmentation, capital strategy, talent development and acquisition, and leadership development. His board experience includes working with high-growth technology companies such as Fleetio, Limble, DebtBook, and A Cloud Guru to name a few.

“TJM Labs has built an impressive position at the intersection of AI and pharmacy, with an enormous opportunity ahead,” said Connolly. “I’m excited to partner with Jonathan, the leadership team, and the Board as the company scales and builds on the momentum it has created.”

TJM Labs has emerged as the leader in pharmacy AI, with its AI agents automating more than 500,000 pharmacy tasks each day across more than 450 pharmacies. The company’s platform enables pharmacies to automate complex, repetitive workflows across existing pharmacy management systems, helping organizations increase capacity and scale operations without a corresponding increase in headcount.

About TJM Labs
TJM Labs is the leading pharmacy AI platform, automating the operational work that slows pharmacies down — prescription intake, data entry, refills, prior authorization, and patient communication — across any pharmacy management system. Built by pharmacists and engineers, TJM’s AI agents process more than 500,000 pharmacy tasks every day across 450+ pharmacies, helping teams handle several times more volume without adding headcount. Backed by $100M raised and the acquisitions of EncoreRx and Pharmesol, TJM Labs is bringing together previously fragmented pharmacy AI capabilities into a single, pharmacy-native platform. Learn more at www.tjmlabs.com.

Joel Makhluf
TJM Labs
joel.makhluf@tjmlabs.com
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube

Media gallery